Send feedback

NRAS p.Ile84Val

c.250A>G · rs376177995 · VCV424299

Uncertain significance Expert panel
Classification
Uncertain significance
ClinVar
Review
Expert panel ★★★☆
ClinVar · 5 submitters
AlphaMissense
likely benign
0.0915 · ACMG-weighted
gnomAD v4.1
Rare
ultra-rare (popmax 0.0164%, mid)
Missense predictors
0/3 damaging
AlphaMissense, REVEL, SaProt
Conditions
2
RASopathy

ClinGen expert panel — RASopathy VCEP

Uncertain Significance for RASopathy. Applied ACMG criteria (verbatim):

BP4

Curation rationale (ClinGen, verbatim)

The NM_002524.5:c.250A>G variant in NRAS is a missense variant predicted to cause substitution of isoleucine by valine at amino acid 84 (p.Ile84Val). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00003870 (5/129184 alleles) in the European (non-Finnish) population (PM2_Supporting, BS1, and BA1 are not met). The computational predictor REVEL gives a score of 0.247, which is below the threshold of 0.3, evidence that does not predict a damaging effect on NRAS function (BP4). In summary, this variant meets the criteria to be classified as uncertain significance for autosomal dominant RASopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy VCEP: BP4. (ClinGen RASopathy VCEP specifications version 2.3; 12/3/2024)

ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.

Computational evidence

Protein change
AlphaMissense0.0915likely benign
REVEL0.247benign-leaning
SaProtLLR -7.18tolerated
⇒ AlphaMissense, REVEL and SaProt all call this tolerated.
Splicing
SpliceAI—not assessed · no allele here is in the release
Constraint at this position
ConservationphyloP 6.2GERP 1.4, phastCons 1
Regional constrainto/e 0.62unconstrained · MANE · 7,622 bp · p 6.3e-09 · regional, not allelic
Overall
CADD21.6PHRED · no single calibrated threshold — expert panels disagree

ClinVar classifies this uncertain; the computational predictors unanimously lean tolerated — a triage signal, not a reclassification

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes
Grpmax group 0.0164% Middle Eastern · 1/6,084 alleles
Filtering AF 0.00145% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.00123%
Overall 0.00161% 26/1,614,002 alleles · ultra-rare
Ancestry group Frequency 1 in
Middle Easterngrpmax 0.0164% 6,084
European (non-Finnish) 0.00212% 47,199

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene
NRAS
Protein
p.Ile84Val
Coding
c.250A>G
MANE Select
NM_002524
dbSNP
rs376177995
Type
single nucleotide variant
Location
chr1:114713840 (GRCh38)
Gene constraint
LOEUF 0.55 · pLI 0.94 · ClinGen HI 0/3 (gnomAD)
Structure
AlphaFold pLDDT 92.56 · 36 PDB
Full NRAS gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/nras-p-ile84val (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown